Arrowhead Research acquires targeted drug delivery company Alvos Therapeutics
Arrowhead Research Corp. (nanomedicines for cancer, obesity, and related metabolic and liver disorders) has acquired privately owned cancer drug discovery company Alvos Therapeutics Inc. (formerly Mercator Therapeutics). Arrowhead issued 315k of its common shares up front (valued at about $2mm) and could issue another $23.5mm in stock earn-outs based on clinical and regulatory achievements, plus additional sales-based earn-outs for the first three drugs developed.
- Site Specific
- Drug Delivery
- Drug Discovery Tools
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.